Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study

Chimeric antigen receptor T‐cell (CAR T) therapy has shown promising efficacy in relapsed and refractory diffuse large B cell lymphoma (DLBCL). While most patients undergo CAR T infusion with active disease, the impact of some clinical variables, such as responsiveness to the pre‐CAR T chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Iovino, Lorenzo, Wu, Qian Vicky, Voutsinas, Jenna, Panaite, Lorena, Mullane, Erin, Lynch, Ryan C., Ujjani, Chaitra, Smith, Stephen D., Gopal, Ajay K., Till, Brian G., Milano, Filippo, Chow, Victor, Gauthier, Jordan, Turtle, Cameron J., Maloney, David G., Shadman, Mazyar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753434/
https://www.ncbi.nlm.nih.gov/pubmed/36453136
http://dx.doi.org/10.1111/jcmm.17550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753434/
https://www.ncbi.nlm.nih.gov/pubmed/36453136
http://dx.doi.org/10.1111/jcmm.17550

Ejemplares similares